Success Metrics

Completion Rate
0%(0/1)
Active Trials
1(33%)
Terminated
1(33%)

Phase Distribution

Ph phase_4
2
67%
Ph phase_2
1
33%

Phase Distribution

0

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 4Post-market surveillance
2(66.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Terminated(1)

Detailed Status

Recruiting1
Terminated1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
0.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (33.3%)
Phase 42 (66.7%)

Trials by Status

recruiting133%
terminated133%
not_yet_recruiting133%

Recent Activity

1 active trials
Showing 3 of 3
recruitingphase_4

Prasugrel Monotherapy Reduced Dose in Acute and Chronic Coronary Syndrome Patients After Percutaneous Coronary Intervention (PROMOTE)

NCT06916520
not_yet_recruitingphase_4

Rivaroxaban for Slow Coronary Flow After PCI in STEMI

NCT07195812
terminatedphase_2

SYNergy Stent® System Implantation With Mandatory Intra-VascularUltra-Sound Guidance and Dual Anti-Platelet Therapy

NCT03606642

Clinical Trials (3)

Showing 3 of 3 trials
NCT06916520Phase 4

Prasugrel Monotherapy Reduced Dose in Acute and Chronic Coronary Syndrome Patients After Percutaneous Coronary Intervention (PROMOTE)

Recruiting
NCT07195812Phase 4

Rivaroxaban for Slow Coronary Flow After PCI in STEMI

Not Yet Recruiting
NCT03606642Phase 2

SYNergy Stent® System Implantation With Mandatory Intra-VascularUltra-Sound Guidance and Dual Anti-Platelet Therapy

Terminated

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3